Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Status and phase: Enrolling; Phase 1

Conditions: Parkinson Disease

Treatments: Drug: Tenofovir Disoproxil Fumarate

Study type: Interventional

Funder types: Other

Identifiers

NCT06356662

KY-2023-198

Details and patient eligibility

About

To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.

Enrollment: 60 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24

Exclusion criteria

• 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders

  2: Or have received deep brain stimulation and other brain surgery

  3: Abnormal liver and kidney function

  4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)

  5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence

  6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor

  7: Pregnant or lactating women and seniors over 65 years of age

  8: Allergy or other contraindications to the investigational drug

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

60 participants in 2 patient groups, including a placebo group

Tenofovir

Experimental group

Description:

patients with parkinson's disease

Treatment:

Drug: Tenofovir Disoproxil Fumarate

Placebo

Placebo Comparator group

Description:

patients with parkinson's disease

Treatment:

Drug: Tenofovir Disoproxil Fumarate